Coya Therapeutics, Inc. (COYA)
2.80
-0.01
(-0.36%)
USD |
NASDAQ |
Nov 06, 10:20
Coya Therapeutics Enterprise Value : 22.74M for Nov. 5, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 05, 2026 | 22.74M |
| November 04, 2026 | 29.07M |
| November 03, 2026 | 29.77M |
| November 02, 2026 | 32.59M |
| October 30, 2026 | 41.50M |
| October 29, 2026 | 50.18M |
| October 28, 2026 | 52.06M |
| October 27, 2026 | 53.47M |
| October 26, 2026 | 49.48M |
| October 23, 2026 | 49.24M |
| October 22, 2026 | 53.93M |
| October 21, 2026 | 53.93M |
| October 20, 2026 | 55.58M |
| October 19, 2026 | 55.34M |
| October 16, 2026 | 56.51M |
| October 15, 2026 | 58.63M |
| October 14, 2026 | 54.87M |
| October 13, 2026 | 61.79M |
| October 12, 2026 | 69.65M |
| October 09, 2026 | 72.94M |
| October 08, 2026 | 73.87M |
| October 07, 2026 | 72.00M |
| October 06, 2026 | 70.59M |
| October 05, 2026 | 70.59M |
| October 02, 2026 | 69.65M |
| Date | Value |
|---|---|
| October 01, 2026 | 67.77M |
| September 30, 2026 | 74.34M |
| September 29, 2026 | 74.81M |
| September 28, 2026 | 73.64M |
| September 25, 2026 | 75.98M |
| September 24, 2026 | 78.33M |
| September 23, 2026 | 75.05M |
| September 22, 2026 | 81.15M |
| September 21, 2026 | 72.94M |
| September 18, 2026 | 71.53M |
| September 17, 2026 | 68.48M |
| September 16, 2026 | 61.44M |
| September 15, 2026 | 65.90M |
| September 14, 2026 | 65.66M |
| September 11, 2026 | 59.56M |
| September 10, 2026 | 62.85M |
| September 09, 2026 | 64.96M |
| September 08, 2026 | 64.96M |
| September 04, 2026 | 68.48M |
| September 03, 2026 | 63.55M |
| September 02, 2026 | 60.50M |
| September 01, 2026 | 62.61M |
| August 31, 2026 | 63.79M |
| August 28, 2026 | 64.49M |
| August 27, 2026 | 70.82M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 7.884B |
| Oncolytics Biotech, Inc. | 52.27M |
| Sangamo Therapeutics, Inc. | 38.97M |
| Sarepta Therapeutics, Inc. | 2.113B |
| Anixa Biosciences, Inc. | 89.83M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -6.638M |
| Revenue (Quarterly) | 0.2437M |
| Total Expenses (Quarterly) | 6.882M |
| EPS Diluted (Quarterly) | -0.283 |
| Gross Profit Margin (Quarterly) | 98.85% |
| Profit Margin (Quarterly) | -2.72K% |
| Earnings Yield | -35.73% |
| Normalized Earnings Yield | -32.83 |